Premium
Early increase in urinary leukotriene E 4 (LTE 4 ) is dependent on allergen dose inhaled during bronchial challenge in asthmatic subjects
Author(s) -
Bancalari L.,
Conti I.,
Giannessi D.,
Lazzerini G.,
Dente F. L.,
De Caterina R.,
Paggiaro P.L.
Publication year - 1999
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1034/j.1398-9995.1999.00199.x
Subject(s) - leukotriene e4 , allergen , excretion , leukotriene , asthma , urine , urinary system , creatinine , inhalation , medicine , endocrinology , allergy , immunology , anesthesia
Background : Urinary leukotriene E 4 (LTE 4 ) excretion is a good marker of the rate of total body production of sulfidopeptide leukotrienes released during allergen challenge. Methods : Twenty‐three subjects with allergic asthma were challenged with inhaled allergen, and the urinary excretion of LTE 4 was determined by immunoenzymatic assay (associated with HPLC separation) at various intervals after challenge. Results : Allergen challenge caused an early airway response (EAR) with a drop in FEV 1 of 40.3±9.9%. This was associated with an increase in urine LTE 4 excretion for 0–3 h after allergen inhalation (296±225.25 pg/mg creatinine) in comparison with baseline values obtained during the night before challenge (101.02±61.97 pg/mg creatinine). Urinary LTE 4 excretion was significantly higher in subjects who inhaled a higher dose of allergen during challenge (LTE 4 during EAR: 211±192 pg/mg creatinine in subjects with inhaled total dose of allergen <0.1 biologic units; 408±223 pg/mg creatinine in subjects with inhaled total dose >0.1 biologic units). All subjects showed a late airway response (LAR) to allergen of different severity, from mild (FEV 1 fall: 15–20%) to severe (>30%); no correlation was found between the increase in urine LTE 4 excreted during LAR (3–7 h after challenge) and the severity of LAR, but only subjects with severe LAR showed a significant increase in LTE 4 during LAR in comparison with baseline value. Conclusions : A release of sulfidopeptide leukotrienes, as evaluated by urinary LTE 4 excretion, can be documented during EAR and LAR to allergen in relation to the dose of inhaled allergen, and it can represent a useful index of the events underlying the airway inflammatory responses during allergen challenge.